BiotechTube

Pazopanib + Paclitaxel

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angiosarcoma

Conditions

Angiosarcoma

Trial Timeline

Jul 1, 2014 → Jul 1, 2020

NCT ID
NCT02212015

About Pazopanib + Paclitaxel

Pazopanib + Paclitaxel is a phase 2 stage product being developed by Novartis for Angiosarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02212015. Target conditions include Angiosarcoma.

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02383251Phase 2Completed
NCT02212015Phase 2Terminated

Competing Products

6 competing products in Angiosarcoma

See all competitors
ProductCompanyStageHype Score
EribulinEisaiPhase 2
39
Avelumab + PaclitaxelMerckPhase 2
31
Pembrolizumab plus LenvatinibMerckPhase 2
42
regorafenibBayerPhase 2
32
Vusolimogene Oderparepvec (VO) + PembrolizumabReplimunePhase 2
36
AGEN2034 + AGEN1884AgenusPhase 2
17